COMP <GO>
CSTL vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Castle Biosciences Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CSTL 4
— MRK 7
■ METRIC PARITY
LAST: $38.51 (+4.99%) • MKT CAP: $1.18B
options-implied-move
—
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CSTL VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CSTL | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.40% | 74.80% | +4.60 | CSTL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -9.30% | 20.70% | -30.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.41% | 3.42% | -1.01 | MRK | /fcf-yield <GO> |
| Operating Margin | -12.40% | 34.30% | -46.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 28.10% | -35.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 3.70% | 1.30% | +2.40 | CSTL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.97 | 5.19 | +1.78 | CSTL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.6 | 51.7 | +12.90 | CSTL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.18B | $361.02B | -$359.84B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CSTL REV | MRK REV | CSTL GROSS % | MRK GROSS % | CSTL FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $344.2M | $65.01B | 79.4% | 74.8% | $28.3M | $12.36B |
| FY 2024 | $332.1M | $64.17B | 81.9% | 76.3% | $36.5M | $18.10B |
| FY 2023 | $219.8M | $60.12B | — | — | -$5.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CSTL // BETA —
MRK // BETA 0.92